Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D; ANRS AC-43 Resistance Study Group. Assoumou L, et al. J Antimicrob Chemother. 2019 May 1;74(5):1417-1424. doi: 10.1093/jac/dkz011. J Antimicrob Chemother. 2019. PMID: 30753724
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, Bouvier-Alias M, Signori-Schmuck A, Montes B, Chaix ML, Amiel C, Santos GD, Ruffault A, Barin F, Peytavin G, Lavignon M, Flandre P, Calvez V. Marcelin AG, et al. Antimicrob Agents Chemother. 2008 Sep;52(9):3237-43. doi: 10.1128/AAC.00133-08. Epub 2008 Jul 14. Antimicrob Agents Chemother. 2008. PMID: 18625773 Free PMC article.
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; ANRS AC11 Resistance Study Group. Marcelin AG, et al. Antimicrob Agents Chemother. 2010 Jan;54(1):72-7. doi: 10.1128/AAC.01051-09. Epub 2009 Nov 9. Antimicrob Agents Chemother. 2010. PMID: 19901096 Free PMC article.
Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits.
Laperche S, Bouchardeau F, André-Garnier E, Thibault V, Roque-Afonso AM, Trimoulet P, Colimon R, Duverlie G, Leguillou-Guillemette H, Lunel F, Bouvier-Alias M, Pawlotsky JM, Henquell C, Schvoerer E, Stoll-Keller F, Chaix ML, Branger M, Gaudy-Graffin C, Rosenberg AR, Pozzetto B, Vallet S, Baazia Y, Izopet J, Lefrère JJ. Laperche S, et al. J Clin Microbiol. 2011 Mar;49(3):1113-5. doi: 10.1128/JCM.01511-10. Epub 2011 Jan 12. J Clin Microbiol. 2011. PMID: 21227989 Free PMC article.
Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG, Descamps D, Tamalet C, Cottalorda J, Izopet J, Delaugerre C, Morand-Joubert L, Trabaud MA, Bettinger D, Rogez S, Ruffault A, Henquell C, Signori-Schmuck A, Bouvier-Alias M, Vallet S, Masquelier B, Flandre P, Calvez V; ANRS AC11 Resistance Study group. Marcelin AG, et al. Antivir Ther. 2012;17(1):119-23. doi: 10.3851/IMP1886. Antivir Ther. 2012. PMID: 22267476
Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.
Dominguez S, Ghosn J, Cassard B, Melica G, Poizot-Martin I, Solas C, Lascaux AS, Bouvier-Alias M, Katlama C, Lévy Y, Peytavin G. Dominguez S, et al. J Antimicrob Chemother. 2012 Jun;67(6):1449-52. doi: 10.1093/jac/dks045. Epub 2012 Mar 5. J Antimicrob Chemother. 2012. PMID: 22396433
HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.
Frange P, Assoumou L, Descamps D, Chéret A, Goujard C, Tran L, Gousset M, Avettand-Fenoël V, Bocket L, Fafi-Kremer S, Guinard J, Morand-Joubert L, Nicot F, Plantier JC, Rogez S, Wirden M, Rouzioux C, Meyer L, Chaix ML; French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups; French ANRS CO 6 PRIMO Cohort the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups. Frange P, et al. J Antimicrob Chemother. 2015 Jul;70(7):2084-9. doi: 10.1093/jac/dkv049. Epub 2015 Feb 26. J Antimicrob Chemother. 2015. PMID: 25885327
Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramière C, Scholtes C, Haïm-Boukobza S, Roque-Afonso AM, Besse B, André-Garnier E, Mohamed S, Halfon P, Pivert A, LeGuillou-Guillemette H, Abravanel F, Guivarch M, Mackiewicz V, Lada O, Mourez T, Plantier JC, Baazia Y, Alain S, Hantz S, Thibault V, Gaudy-Graffin C, Bouvet D, Mirand A, Henquell C, Gozlan J, Lagathu G, Pronier C, Velay A, Schvoerer E, Trimoulet P, Fleury H, Bouvier-Alias M, Brochot E, Duverlie G, Maylin S, Gouriou S, Pawlotsky JM, Morand P. Larrat S, et al. J Clin Microbiol. 2015 Jul;53(7):2195-202. doi: 10.1128/JCM.03633-14. Epub 2015 Apr 29. J Clin Microbiol. 2015. PMID: 25926499 Free PMC article.
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.
Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group. Raymond S, et al. Clin Infect Dis. 2018 May 2;66(10):1588-1594. doi: 10.1093/cid/cix1070. Clin Infect Dis. 2018. PMID: 29244143 Free PMC article.
63 results